ReviewJournal of clinical medicine2022
An Update on the Management of Acute High-Risk Pulmonary Embolism.
Review in Journal of clinical medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Frequency-domain band-pass filtering enhanced pulsation method for pulmonary embolism diagnosis and risk stratification: a two-center retrospective study.Critical care (London, England) · 2026Article
- Interventional Management of Intermediate-High-Risk Pulmonary Embolism: Current Evidence, Patient Selection and Personalised Treatment Strategies.Journal of clinical medicine · 2026Review
- Intracavitary percutaneous thromboaspiration as a rescue strategy across high-risk scenarios: a case series.European heart journal. Case reports · 2026Article
- Outcome of Patients Presenting With High-Risk Pulmonary Embolism Treated With Mechanical Thrombectomy: A Subgroup Analysis From the STRIKE-PE Study.Journal of the Society for Cardiovascular Angiography & Interventions · 2026Article
- Clinical Outcomes and Treatment Strategies in Catastrophic High-Risk Pulmonary Embolism: A Retrospective Analysis.Journal of cardiovascular development and disease · 2025Article
- Evolving Management of Acute Pulmonary Embolism with Extracorporeal Membrane Oxygenation-A Narrative Review.Journal of clinical medicine · 2025Review
- Risk Stratification and Management of Intermediate- and High-Risk Pulmonary Embolism.Journal of clinical medicine · 2024Review
- Review
- Mechanical Circulatory Support Devices in Patients with High-Risk Pulmonary Embolism.Journal of clinical medicine · 2024Review
- Management of high-risk pulmonary embolism in the emergency department: A narrative review.The American journal of emergency medicine · 2024Review
- Development and validation of prediction models for death within 6 months after cardiac arrest.Frontiers in cardiovascular medicine · 2024Article
- Intraoperative circulatory arrest secondary to high-risk pulmonary embolism. Case series and updated literature review.BMC anesthesiology · 2023Review
- Case Report: emergent percutaneous directional thrombectomy in a patient with cardiogenic shock and large mobile thrombus in the right atrium.European heart journal. Case reports · 2023Article
- Hemodynamic and respiratory support in pulmonary embolism: a narrative review.Frontiers in medicine · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hemodynamic instability and right ventricular (RV) dysfunction are the key determinants of short-term prognosis in patients with acute pulmonary embolism (PE). High-risk PE encompasses a wide spectrum of clinical situations from sustained hypotension to cardiac arrest. Early recognition and treatment tailored to each individual are crucial. Systemic fibrinolysis is the first-line pulmonary reperfusion therapy to rapidly reverse RV overload and hemodynamic collapse, at the cost of a significant rate of bleeding. Catheter-directed pharmacological and mechanical techniques ensure swift recovery of echocardiographic parameters and may possess a better safety profile than systemic thrombolysis. Further clinical studies are mandatory to clarify which pulmonary reperfusion strategy may improve early clinical outcomes and fill existing gaps in the evidence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.